Cash J D, Spencely M
Br Med J. 1976 Sep 18;2(6037):682-4. doi: 10.1136/bmj.2.6037.682.
The demand for blood products containing factor VIII for treating patients with haemophilia A in south-east Scotland was reviewed. From 1961 to 1975 the demand for fresh frozen plasma (FFP), cryoprecipitate (CP), and antihaemophilic factor (AHF) increased by seven and a half times, while total donations increased by only a third. Patients with severe haemophilia A treated at the regional haemophilia centre used about 85% of the factor VIII issued in 1971-4, most of which was used on demand. A patient with severe haemophilia A on unlimited ondemand home treatment would need about 500 units of factor VII/kg body weight/year, and a regional haemophilia centre, treating moderate and mild cases as well as severe ones, would use 15000 units/patient/year. Altogether about 50 million units of factor VIII will be needed each year in the UK. Although cryoprecipitate is much harder to store and administer than AHF, its yield from plasma may be far greater and its cost far smaller. Unless the blood transfusion services receive increased amounts of money and reappraise their functions and operation, it seems likely that they will have to rely increasingly on commercial (and costly) sources for the major plasma fractions.
对苏格兰东南部治疗甲型血友病患者所需含凝血因子 VIII 的血液制品需求进行了审查。1961 年至 1975 年期间，新鲜冰冻血浆（FFP）、冷沉淀（CP）和抗血友病因子（AHF）的需求增长了七倍半，而献血总量仅增长了三分之一。在地区血友病中心接受治疗的重度甲型血友病患者使用了 1971 年至 1974 年发放的约 85% 的凝血因子 VIII，其中大部分是按需使用的。一名接受无限制按需家庭治疗的重度甲型血友病患者每年每公斤体重约需 500 单位凝血因子 VII，而一个同时治疗中度、轻度和重度病例的地区血友病中心每年每位患者将使用 15000 单位。英国每年总共大约需要 5000 万单位的凝血因子 VIII。尽管冷沉淀比抗血友病因子更难储存和管理，但其从血浆中的产量可能远高于抗血友病因子，成本也远低于抗血友病因子。除非输血服务机构获得更多资金并重新评估其职能和运营，否则它们似乎将越来越依赖商业（且成本高昂）来源获取主要的血浆成分。
